营养补充品中刺激剂的分析测定

介绍营养补充品中刺激剂的毛细管气相色谱和气相色谱质谱联用检测方法.试样采用碱提,液-液分配提取,以HP-5毛细管柱为分离柱,用氮磷检测器测定.实验结果表明:该方法操作简便,分析速度快,结果可靠.添加平均回收率为75.4%～143.1%,相对标准偏差为0.27%～5.5%,检出限为5～40μg/L.     

Prospective Relations Between Melancholia and Substance Use Disorders

Examining associations between subtypes of major depressive disorder (MDD) and substance use disorders (SUDs) might elucidate mechanisms of comorbidity between MDD and SUDs. This study evaluated prospective relations between SUDs and melancholic MDD. A cohort of community-dwelling participants with lifetime history of MDD (N = 460) were assessed for DSM-IV mental disorders using structured clinical interviews at ages 24 and 30. Stimulant use disorders and melancholic MDD were prospective risk factors for each other over the 6-year-period following the age-24 assessment. Associations were robust when controlling for clinical severity/chronicity. Alcohol and cannabis use disorders were not robustly associated with melancholia.     

Gastrointestinal Decontamination: Maybe We'Re Both Right (Commentary)

Context. Naphyrone (naphthylpyrovalerone) is a cathinone derivative and recreational drug related to mephedrone. Case. We report a 31-year-old man who ingested a dose of naphyrone (100 mg), which produced acute sympathomimetic toxicity with restlessness, insomnia, anxiety, and hallucinations lasting for 2 days. Naphyrone was detected in the patient's plasma by gas chromatography with mass spectrometry at concentrations of 0.03 and 0.02 mg/L, 40 and 60 h after drug intake, respectively. Discussion. Based on the present case report and user web-reports, as well as on the chemical structure and pharmacological characteristics, naphyrone produces stimulant-like psychotropic effects and sympathomimetic toxicity.     

Workaholism is still a useful construct

Medical provision of orally-administered stimulants is a harm reduction technique that could reduce suffering and slow the spread of AIDS among cocaine misusers in Vancouver, B.C., Canada. However, experimentation with stimulant maintenance will be difficult to carry out until the public's exaggerated fears of cocaine and other stimulants, engendered by a prolonged “War on Drugs”, have subsided. This article explores the prospects for stimulant maintenance by (1) reviewing the actual dangers and benefits arising from use of cocaine and other stimulants, (2) describing small scale stimulant maintenance programs that already exist in various countries, and (3) drawing from Vancouver's experience with methadone maintenance to propose first steps towards stimulant maintenance. Although we focus our analysis on Vancouver, we believe it has wider applicability.     

Pseudoephedrine and circadian rhythm interaction on neuromuscular performance

This study analyzed the effects of pseudoephedrine (PSE) provided at different time of day on neuromuscular performance, side effects, and violation of the current doping cut‐off threshold [World Anti‐Doping Agency (WADA)]. Nine resistance‐trained males carried out bench press and full squat exercises against four incremental loads (25%, 50%, 75%, and 90% one repetition maximum [1RM]), in a randomized, double‐blind, cross‐over design. Participants ingested either 180 mg of PSE (supra‐therapeutic dose) or placebo in the morning (7:00 h; AM_PLAC and AM_PSE) and in the afternoon (17:00 h; PM_PLAC and PM_PSE). PSE enhanced muscle contraction velocity against 25% and 50% 1RM loads, only when it was ingested in the mornings, and only in the full squat exercise (4.4–8.7%; P < 0.05). PSE ingestion raised urine and plasma PSE concentrations (P < 0.05) regardless of time of day; however, cathine only increased in the urine samples. PSE ingestion resulted in positive tests occurring in 11% of samples, and it rose some adverse side effects such us tachycardia and heart palpitations. Ingestion of a single dose of 180 mg of PSE results in enhanced lower body muscle contraction velocity against low and moderate loads only in the mornings. These mild performance improvements are accompanied by undesirable side effects and an 11% risk of surpassing the doping threshold.     

Caffeine content of pre‐workout supplements commonly used by Australian consumers

The stimulant properties of caffeine are often promoted in pre‐workout supplements (PWS) to assist with training, reduce the perception of fatigue, and for some brands, assist body fat loss. While manufacturers of PWS often indicate the inclusion of significant amounts of caffeine, no independent verification of the caffeine content of these products exists. The aim of this investigation was to independently assess the caffeine content of popular PWS in Australia and compare these values to nutrition information panel data. Fifteen PWS were tested for their caffeine content (both within and between batches of the same product). The caffeine content of selected PWS ranged from 91 to 387 mg·serve^?1. Only 6 of the 15 PWS nutrition information panels included details on caffeine content. The percent of caffeine present ranged from 59% to 176% of packaging claims. All but one PWS contained a variation of caffeine within and between batches that was considered “practically” significant (ie, ≥40 mg·serve^?1 variation). Consumers are likely to be exposed to large and variable caffeine doses if ingesting PWS. Product information panels do little to improve consumer awareness of likely caffeine intakes.     

Enzyme Immunoassay for Mabuterol,A Selective β2-Adrenergic Stimulant in the Trachea

A sensitive double antibody and heterologous enzyme immunoassay for mabuterol was established. For competitive reactions, antibody raised against diazotized mabuterol-human serum albumin was incubated with a mixture of diazotized mabuterol analog (RC-1) labeled with β-D-galactosidase and standard or sample. Free and antibody-bound enzyme hapten were separated using anti-rabbit IgG immobilized on polystyrene balls. Activity of the enzyme on the solid phase was fluorometrically determined. The present immunoassay allows detection of 0.5 to 100 pg/tube of mabuterol.

Pharmacokinetic behavior of this agent in human plasma and urine was studied after a single oral administration (50 yg). The maximum level was achieved after 2–3 hrs with approximately 280 pg mabuterol /ml of plasma and the half life of mabuterol was estimated to be 19.5 hrs. Cumulative amount of mabuterol in the first 72 hrs urine was 64.3 ± 13.2% of the administered dose.     

Lisdexamfetamine: chemistry,pharmacodynamics, pharmacokinetics,and clinical efficacy,safety, and tolerability in the treatment of binge eating disorder

Introduction: The indications for lisdexamfetamine (LDX), a central nervous system stimulant, were recently expanded to include treatment of moderate to severe binge eating disorder (BED).

Areas covered: This review aims to describe the chemistry and pharmacology of LDX, as well as the clinical trials investigating the efficacy and safety of this medication for the management of BED.

Expert opinion: LDX is the first medication with United States Food and Drug Administration approval for the treatment of BED. It is an inactive prodrug of d-amphetamine that extends the half-life of d-amphetamine to allow for once daily dosing. D-amphetamine acts primarily to increase the concentrations of synaptic dopamine and norepinephrine. Metabolism of LDX to d-amphetamine occurs when peptidases in red blood cells cleave the covalent bond between d-amphetamine and l-lysine. D-amphetamine is then further metabolized by CYP2D6. Excretion is primarily through renal mechanisms. In clinical trials, LDX demonstrated statistical and clinical superiority over placebo in reducing binge eating days per week at doses of 50 and 70 mg daily. Commonly reported side effects of LDX include dry mouth, insomnia, weight loss, and headache, and its use should be avoided in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia or coronary artery disease. As with all CNS stimulants, risk of abuse needs to be assessed prior to prescribing.